Oxford, United Kingdom — November 4, 2025 — Leads & Copy — Enara Bio will present its newly discovered cancer-specific target DARKFOX™ at the Society for Immunotherapy of Cancer (SITC) 2025 annual meeting, which takes place November 5-9 in National Harbor, MD.
DARKFOX is the first in a new category of validated Dark Antigens, delivering on translating the dark genome into a new class of clinically actionable Dark Antigens. It demonstrates high tumor specificity, homogeneous expression in tumors, and high prevalence in significant patient populations including lung, breast, and GI cancers.
ENA101, a first-in-class bispecific T cell engager against DARKFOX, has been developed and optimized using Enara’s EnTiCE platform and demonstrates high selectivity, potent cytotoxicity, and robust T cell activation. This supports a large therapeutic window and strong potential to transform the standard of care. ENA101 is advancing into IND-enabling studies with a clear development path to submission in 2026.
Enara is investing in EDAPT, its Dark Antigen discovery platform, and recently expanded its discovery capabilities to include Dark Cell Surface Proteins.
Abstracts are available on the SITC website and oral presentation details are below:
Abstract number: 1298
Oral Presentation: Joe Dukes, Chief Scientific Officer, Enara Bio
Concurrent Session 207c: The Dark Genome: Making Cryptic Epitopes Actionable
Saturday 8 November 3.30-5.10pm ET
Scheduled presentation time 4.35pm ET
Poster Session: Poster Hall – Saturday 8 November
Kevin Pojasek, President & CEO, info@enarabio.com
Stacey Davis, CBO & CFO, stacey.davis@enarabio.com
Frazer Hall, Mark Swallow, MEDiSTRAVA , enarabio@medistrava.com
Source: Enara Bio
